(BUSINESS WIRE) This strategic acquisition brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks and cultures.
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
-
-
Foreign Direct Investment (FDI) in Brownfield pharma sector has been permitted upto 74% under automatic route; and FDI beyond 74% and upto 100% is allowed under Government approval route.
-
Lupin's Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. has entered into a strategic asset purchase agreement with Shionogi & Co., Ltd. on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorization of the products to Kyowa.
(adsbygoogle = window.adsbygoogle || []).push({}); -
The Competition Commission of India (Commission) has found the Karnataka Chemists and Druggist Association (KCDA) and Lupin Ltd. (Lupin) to be in contravention of the provisions of the Competition Act, 2002 (the Act). In a case filed by M/s Maruti & Co., it was brought to the notice of the Commission that KCDA restraints pharmaceutical companies from appointing new stockists in the State of Karnataka unless a No Objection Certificate (NOC) is obtained from it.
-
Vanda Pharmaceuticals Inc. (Vanda), a specialty pharmaceutical company, announced that Hetlioz (tasimelteon) is now available for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in Germany.
-
Vaccinex, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential treatment for Huntington’s disease (HD).
-
Shire plc, a leading global biotechnology company, announced that the US Food and Drug Administration (FDA) has approved the Baxject III reconstitution system for Adynovate [Antihemophilic Factor, (Recombinant), PEGylated].
-
Ipsen announced that the U.S. Food and Drug Administration (FDA) has approved Dysport® (abobotulinumtoxinA) for injection for the treatment of pediatric lower limb (PLL) spasticity in children two years of age and older.
-
The growing use of biologics, drugs with newer mechanisms of action, and combination therapies are trending in the global rheumatoid arthritis (RA) market. BCC Research reveals in its new report that the biosimilars market should grow at a torrential five-year (2015-2020) compound annual growth rate (CAGR) of 71%.
Rheumatoid arthritis is a chronic inflammatory disease characterized by progressive joint damage, disability and systemic complications. The goal of treatment in RA is to achieve clinical remission. When remission, defined as the absence of signs and symptoms of inflammation, is unattainable, the target of treatment is to lower disease activity, particularly in patients with established RA. This report provides perspective on drugs and therapies used in the management of RA.
The global market for therapies for RA is expected to grow from USD 19.9 billion in 2015 to nearly USD 21.3 billion by 2020, reflecting a five-year CAGR of 1.3%.As a therapeutic class, anti-interleukin biologics should grow from nearly USD 1.2 billion in 2015 to USD 1.5 billion in 2020 on a five-year CAGR of 4.4%. Biosimilars as a therapeutic class should reach nearly USD 5.4 billion in 2020 on a five-year CAGR of 71.0%, up from an anticipated USD 368 million in 2015.
The market for RA treatments in the seven major markets (U.S., France, Italy, Germany, Spain, U.K., and Japan) is expected to reach USD 16.3 billion and USD 17.2 billion in 2015 and 2020, respectively, reflecting a five-year CAGR of approximately 1%. The genericization and introduction of biosimilars for major products such as etanercept, infliximab and rituximab will impact market growth.
The market in the rest of the world (RoW), including India and China, should total USD 3.6 billion and USD 4.1 billion in 2015 and 2020, respectively, growing at a five-year CAGR of about 2.5%. The introduction of cheaper biosimilars and Janus kinase inhibitors (JAKs) will drive market growth.
The biosimilars market will witness incredible growth both in the RoW and globally. Their robust adoption is expected in the seven major markets, where healthcare providers are pushing for more affordable options to the high cost of biologics therapy, particularly for chronic immunological diseases.
"Worldwide, the value of the biosimilars market will grow from about USD 174 million in 2014 to almost USD 5.4 billion in 2020 due to the introduction of biosimilars," says BCC Research analyst Geeta Ogra Bedi. "Presently, a growing number of biosimilars are in the late stage of clinical development. Although biosimilars don't promise the kind of cost savings generated by their small-molecule counterparts, they still possess the ability to yield significant cost savings."
-
All animals begin life as a single cell from which arise the many different cell types, such as heart, lung, blood, etc., that are specific to that type of animal. However, once the process of cell differentiation has led to many different tissues, each organism has a new, opposite imperative – keeping new cells in each type of tissue the same as their brethren. Cancers arise in a tissue when a cell becomes different from its neighbors and thus represent a failure to maintain this critical uniformity.
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
